Deutsche Bank reiterated its Buy rating on Medtronic MDT after the company announced its quarterly results.
In a research report published today, Deutsche Bank states, "F4Q sales were in line but EPS of $0.90 was $0.02 below First Call Cons and
$0.03 below implied guidance due to Greece write-down ($0.01), minority inv
write-offs ($0.01), and an ICD shortfall partially offset by other businesses and
expense controls. FY12 guidance was disappointing on the surface, but after
reviewing the assumptions seems achievable and leaves opportunity for upside.
Given the valuation, new products, and new CEO, we continue to rate MDT Buy."
At the moment, Deutsche Bank has a price target of $46 on Medtronic. On Tuesday, Medtronic lost 0.92% to close the day at $40.88. Its shares continued to slide in today's pre-market trading as well, falling 0.59% to $40.64.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in